CoChat

Broad therapeutic treatment window of [Nle4, D-Phe7]α-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils

Open access
Giuliani, Daniela, Leone, Sheila, Mioni, Chiara, Bazzani, Carla, Zaffe, Davide, Botticelli, Annibale R., Altavilla, Domenica, Galantucci, Maria, Minutoli, Letteria, Bitto, Alessandra, Squadrito, Francesco, Guarini, Salvatore · 2006 · European Journal of Pharmacology
Cited by 40

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Melanocortin peptides have been shown to produce neuroprotection in experimental ischemic stroke. The aim of the present investigation was to identify the therapeutic treatment window of melanocortins, and to determine whether these neuropeptides chronically protect against damage consequent to brain ischemia. A 10-min period of global cerebral ischemia in gerbils, induced by occluding both common carotid arteries, caused impairment in spatial learning and memory (Morris test: four sessions from 4 to 67 days after the ischemic episode), associated with neuronal death in the hippocampus. Treatment with a nanomolar dose (340 microg/kg i.p., every 12 h for 11 days) of the melanocortin analog [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone (NDP-alpha-MSH), starting 3-18 h after the ischemic episode, reduced hippocampal damage with improvement in subsequent functional recovery. The protective effect was long-lasting (67 days, at least) with all schedules of NDP-alpha-MSH treatment; however, in the latest treated (18 h) gerbils, some spatial memory deficits were detected. Pharmacological blockade of melanocortin MC(4) receptors prevented the protective effects of NDP-alpha-MSH. Our findings indicate that, in conditions of brain ischemia, melanocortins can provide strong and long-lasting protection with a broad therapeutic treatment window, and with involvement of melanocortin MC(4) receptors, 18 h being the approximately time-limit for stroke late treatment to be effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2006.03.038

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 40

Metadata

Authors
Giuliani, D., Leone, S., Mioni, C., Bazzani, C., Zaffe, D., Botticelli, A. R., Altavilla, D., Galantucci, M., Minutoli, L., Bitto, A., Squadrito, F., & Guarini, S.
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2006-05
Volume
538
Issue
1-3
Pages
48-56
ISSN
0014-2999 (ISSN-L)
OpenAlex
W2145381340
Cited by
40
References
6
FWCI
1.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Broad therapeutic treatment window of [Nle4, D-Phe7]α-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. https://app.cochat.ai/papers/10.1016/j.ejphar.2006.03.038
The paper
Giuliani, D., Leone, S., Mioni, C., Bazzani, C., Zaffe, D., Botticelli, A. R., Altavilla, D., Galantucci, M., Minutoli, L., Bitto, A., Squadrito, F., & Guarini, S. (2006). Broad therapeutic treatment window of [Nle4, D-Phe7]α-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2006.03.038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.